Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Terbinafine topical - Celtic Pharma

Drug Profile

Terbinafine topical - Celtic Pharma

Alternative Names: IDEA-067; TDT-067; Terbinafine cutaneous suspension

Latest Information Update: 11 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IDEA
  • Developer Celtic Pharma
  • Class Antifungals; Carrier proteins; Naphthalenes; Small molecules
  • Mechanism of Action Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Onychomycosis

Most Recent Events

  • 11 May 2015 No recent reports on development identified - Phase-III for Onychomycosis in USA, Iceland and Germany (Topical)
  • 30 May 2013 Biomarkers information updated
  • 30 Jun 2012 Celtic Pharma completes a phase II trial for Onychomycosis in USA (NCT01790165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top